Personalis at Liquid Biopsy for Precision Oncology Summit US: 10th-11th February 2022
NeXT Personal: Next Generation MRD Testing for Solid Tumors

February 10: 12:30-1:00 PM PST
The ability to monitor and predict molecular recurrence at the earliest timepoints during or after curative therapy in patients previously diagnosed with cancer may inform precision treatment regimens, or spare patients from costly side effects. Here we discuss NeXT Personal, an advanced next generation MRD platform optimized for sensitivity to detect cancer at the earliest timepoints.
Connect with us at Liquid Biopsy for Precision Oncology Summit US 2022